secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001628280-23-027779
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Q3 net loss widens to $103M; revenue drops 51%; milestones from GSK and Takeda
--------------------------------------------------------------------------------

- Revenue $15.8M (down 51% YoY from $32.4M); net loss $102.9M (vs $72.0M loss); diluted EPS -$0.96 (vs -$0.68).
- Cash and investments $494.5M vs $482.3M at Sept 30, 2022; total assets $795.9M.
- Earned $30M milestone from GSK for Phase 2b start of ARO-HSD (NASH); $40M from Takeda for first patient in Phase 3 REDWOOD of fazirsiran.
- Completed enrollment of PALISADE Phase 3 for ARO-APOC3; data readout expected Q2 2024.
- R&D Day: ARO-RAGE inhaled dose of 184mg achieved 90% mean knockdown; TRiM platform shows CNS and adipose delivery advances.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828023027779/0001628280-23-027779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828023027779/arwr-20230807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-027779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer